Methods and compositions for correction of cardiac conduction disturbances
View Patent ↗The invention provides methods for establishing electrical coupling between cardiomyocytes and recombinant cells which have been genetically engineered to express a connexin protein such as connexin 43 (Cx43) protein. The invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin-expressing cells can be used for repair of cardiac tissue and for treatment of cardiac disease by transplantation into cardiac tissue.
1. A method of establishing an electrical connection between a recombinant mammalian cell and a myocardial cell, the method comprising:
contacting a myocardial cell of a subject with a recombinant mammalian cell genetically modified to express a connexin 43 protein;
wherein the recombinant mammalian cell is a skeletal muscle cell or a mesenchymal stem cell, and wherein the cell is autologous or allogenic to the subject, and wherein said contacting is performed by injection into cardiac tissue of the subject, or is performed by cardiovascular infusion into the subject, and is sufficient to establish an electrical connection between the myocardial cell and the recombinant mammalian cell.
2. The method of claim 1 , wherein the recombinant mammalian cell is, a mesenchymal stem cell.
3. The method of claim 1 , wherein the recombinant mammalian cell is a skeletal muscle cell.
4. The method of claim 3 , wherein the skeletal muscle cell is an adult skeletal muscle cell.
5. The method of claim 1 , wherein after the electrical connection between the recombinant mammalian cell and the myocardial cell is established, the recombinant mammalian cell has conductive characteristics similar to the myocardial cell.
6. A method of establishing an electrical connection between a recombinant skeletal muscle cell and a myocardial cell, the method comprising:
contacting a myocardial cell of a subject with a recombinant skeletal muscle cell genetically modified to express a connexin 43 protein, wherein the recombinant cell is autologous or allogenic to the subject, and said contacting is performed by injection into cardiac tissue of the subject, or is performed by cardiovascular infusion, and is sufficient to establish an electrical connection between the myocardial cell and the recombinant skeletal muscle cell so that the recombinant skeletal muscle cell has conductive characteristics similar to the myocardial cell.
7. The method of claim 6 , wherein the skeletal muscle cell is an adult skeletal muscle cell.
8. A method for treating a cardiac conduction disturbance in a host, the method comprising:
introducing into cardiac tissue of said host a therapeutically effective amount of a recombinant mammalian cell genetically modified to express a connexin 43 proteins; wherein the recombinant mammalian cell is a skeletal muscle cell or a mesenchymal stem cell, and wherein the cell is autologous or allogenic to the host,
wherein said introducing is performed by injection into cardiac tissue of the host, or is performed by cardiovascular infusion into the host, and
wherein said introducing is effective to establish an electrical connection between the recombinant cell and a myocardial cell of the host cardiac tissue; and
wherein the cardiac conduction disturbance in the host is treated.
9. The method of claim 8 , wherein the recombinant cell is a skeletal muscle cell.
10. The method of claim 9 , wherein the skeletal muscle cell is an adult skeletal muscle cell.
11. The method of claim 8 , wherein said introducing comprises implanting the recombinant cell into an infarct region of the cardiac tissue.